Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results

BEACON Trial of BEAM-101 in Sickle Cell Disease Progressing with Consented Patients Projected to Fill Sentinel Cohort and to Initiate Expansion Cohort First Patient Consented in Phase 1/2 Trial of...

Related Keywords

North Carolina ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,John Evans ,Dan Budwick ,David Liu ,Chelcie Lister ,Mitchell Weiss ,Program Now ,Jude Children Research Hospital ,Company To Accelerate Development ,Exchange Commission ,Beam Therapeutics Inc ,Nasdaq ,Strategic Communications ,Research Development Rd Expenses ,Sickle Cell Disease Progressing ,Consented Patients Projected ,Fill Sentinel Cohort ,Initiate Expansion ,Patient Consented ,Third Quarter ,Accelerate Development ,Program Now Expected ,First In Vivo Liver Regulatory Filing ,First Quarter ,Cash Equivalents ,Marketable Securities ,Second Quarter ,Engineered Stem Cell Antibody Paired Evasion ,Jude Children ,Research Hospital ,Jonathan Yen ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Consolidated Balance Sheet Data ,Consolidated Statement ,Months Ended June ,Markets ,